<DOC>
	<DOCNO>NCT00461851</DOCNO>
	<brief_summary>This Phase II , nonrandomized multicenter study design evaluate time progression response proportion patient advance metastatic transitional cell carcinoma bladder receive 6 cycle gemcitabine , carboplatin sorafenib maintenance sorafenib .</brief_summary>
	<brief_title>Trial Gemcitabine , Carboplatin , Sorafenib Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologic documentation diagnosis transitional cell carcinoma bladder , urethra , ureter , renal pelvis Unresectable , locally advanced metastatic disease CrCl ≥ 60 ml/min serum creatinine &lt; 1.5 ≥ 4 week since prior RT ECOG Performance Status 0 1 ( Appendix I ) Age ≥ 18 year age Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) prior study entry duration study participation . Men woman use adequate birth control least 2 week last administration sorafenib . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . Adequate bone marrow , liver renal function assess follow : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Total bilirubin ≤ 1.5 time ULN ALT AST ≤ 2.5 time ULN ( ≤ 5 x ULN patient liver involvement ) INR &lt; 1.5 PT/PTT within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR measure prior initiation sorafenib monitor least weekly , define local standard care , INR stable . Prior treatment systemic chemotherapy ( prior intravesical chemotherapy permit , adjuvant therapy permit &gt; 12 month lapse ) Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Cardiac disease : Congestive heart failure &gt; class II NYHA . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . History stroke within six month Clinically significant peripheral vascular disease Known brain metastasis . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Sorafenib contraindicate patient know severe hypersensitivity sorafenib excipients . Known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. Active clinically serious infection &gt; CTCAE Grade 2 . Thrombolytic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 week first dose study drug Any hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 week first dose study drug Evidence history bleed diathesis coagulopathy Major surgery , significant traumatic injury within 4 week first study drug Use St. John 's Wort rifampin ( rifampicin ) Known suspect allergy sorafenib agent give course trial Any condition impair patient 's ability swallow whole pill Any malabsorption problem Anticipation need major surgical procedure course study Pregnant ( positive pregnancy test ) lactate History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Inability comply study and/or followup procedure History persistent gross hematuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Advanced/Metastatic Bladder Carcinoma</keyword>
</DOC>